Anal squamous cell carcinoma: Impact of radiochemotherapy evolution over years and an explorative analysis of MRI prediction of tumor response in a mono-institutional series of 131 patients.
IMRT (intensity modulated radiation therapy)
anal cancer (AC)
mri
predictive modeling
radiotherapy–chemotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
06
2022
accepted:
27
09
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
11
11
2022
Statut:
epublish
Résumé
Radiochemotherapy (RCHT) for the treatment of anal squamous cell carcinoma (ASCC) has evolved dramatically, also thanks to intensity-modulated RT (IMRT) and 3D image guidance (3D IGRT). Despite most patients presenting fair outcomes, unmet needs still exist. Predictors of poor tumor response are lacking; acute toxicity remains challenging; and local relapse remains the main pattern of failure. Between 2010 and 2020, ASCC stages I-III treated with 3D conformal radiotherapy or IMRT and CDDP-5FU or Mytomicine-5FU CHT were identified. Image guidance accepted included 2D IGRT or 3D IGRT. The study endpoints included freedom from locoregional recurrence (FFLR), colostomy free survival (CFS), freedom from distant metastasis (FFDM), overall survival (OS), and acute and late toxicity as measured by common terminology criteria for adverse events (CTCAE) version 5.0. An exploratory analysis was performed to identify possible radiomic predictors of tumor response. Feature extraction and data analysis were performed in Python™, while other statistics were performed using SPSS A total of 131 patients were identified. After a median FU of 52 months, 83 patients (63.4%) were alive. A total of 35 patients (26.7%) experienced locoregional failure, while 31 patients (23.7%) relapsed with distant metastasis. Five year FFLR, CFS, DMFS and PS resulted 72.3%, 80.1%, 74.5% and 64.6%. In multivariate analysis, 2D IGRT was associated with poorer FFLR, OS, and CFS (HR 4.5, 4.1, and 5.6, respectively); 3DcRT was associated with poorer OS and CFS (HR 3.1 and 6.6, respectively). IMRT reduced severe acute gastro-intestinal (GI) and severe skin acute toxicity in comparison with 3DcRT. In the exploratory analysis, the risk of relapse depended on a combination of three parameters: Total Energy, Gray Level Size Zone Matrix's Large Area High Gray Level Emphasis (GLSZM's LAHGLE), and GTV volume. Advances in radiotherapy have independently improved the prognosis of ASCC patients over years while decreasing acute GI and skin toxicity. IMRT and daily 3D image guidance may be considered standard of care in the management of ASCC. A combination of three pre-treatment MRI parameters such as low signal intensity (SI), high GLSZM's LAHGLE, and GTV volume could be integrated in risk stratification to identify candidates for RT dose-escalation to be enrolled in clinical trials.
Identifiants
pubmed: 36353538
doi: 10.3389/fonc.2022.973223
pmc: PMC9639749
doi:
Types de publication
Journal Article
Langues
eng
Pagination
973223Informations de copyright
Copyright © 2022 Bonù, La Mattina, Singh, Toraci, Spiazzi, Terraneo, Barbera, Vitali, Frassine, Guerini, Triggiani, Tomasini, Morelli, Imbrescia, Andreuccetti, Frittoli, Pittiani, Grazioli, Portolani, Nicosia, Albano, Bertagna, Magrini and Buglione.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Radiat Oncol. 2019 Apr 3;14(1):57
pubmed: 30943992
Lancet Oncol. 2013 May;14(6):516-24
pubmed: 23578724
Ann Surg Oncol. 2007 Oct;14(10):2780-9
pubmed: 17638059
Int J Colorectal Dis. 2020 Apr;35(4):685-694
pubmed: 32036405
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30
pubmed: 19117696
J Clin Oncol. 2020 Aug 1;38(22):2510-2518
pubmed: 32530769
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
J Stat Softw. 2018 Aug;86:
pubmed: 30288153
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
BMC Cancer. 2015 Apr 14;15:281
pubmed: 25885556
Lancet Oncol. 2017 Jul;18(7):e379-e393
pubmed: 28677574
Br J Surg. 2005 May;92(5):605-14
pubmed: 15739215
Cancers (Basel). 2021 Apr 09;13(8):
pubmed: 33918650
Am J Surg. 2011 May;201(5):628-33
pubmed: 21545912
AIDS. 1994 Mar;8(3):283-95
pubmed: 8031509
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1455-62
pubmed: 22401917
Radiother Oncol. 2011 Jan;98(1):99-104
pubmed: 21168927
J Pers Med. 2021 May 18;11(5):
pubmed: 34069862
Radiother Oncol. 2014 Jun;111(3):330-9
pubmed: 24947004
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Clin Infect Dis. 2020 Mar 3;70(6):1176-1185
pubmed: 31044245
Ann Surg Oncol. 2007 Feb;14(2):478-83
pubmed: 17103253
J Clin Oncol. 2008 May 20;26(15):2550-7
pubmed: 18427149
Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):146-157
pubmed: 34400269
J Clin Oncol. 2012 Dec 10;30(35):4344-51
pubmed: 23150707
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e707-12
pubmed: 21641733
Eur J Cancer. 2020 Mar;128:7-16
pubmed: 32109852
Radiother Oncol. 2019 May;134:119-126
pubmed: 31005205